ID

14448

Descrizione

Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids (ICS) With or Without Other Controllers; ODM derived from: https://clinicaltrials.gov/show/NCT02449473

collegamento

https://clinicaltrials.gov/show/NCT02449473

Keywords

versioni (1)
  1. 15/04/16 15/04/16 -
Caricato su

15 aprile 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Asthma NCT02449473

Inglese

Eligibility Asthma NCT02449473

1 moduli  
  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT02449473
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. age 18 to 75 years
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
2. documented physician-diagnosed asthma for at least 12 months prior to enrolment (v1)
Descrizione

Asthma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0004096
3. documented treatment with an asthma controller regimen requiring treatment with ics (minimum dose of ≥ 250 ug fluticasone propionate via dry powder inhaler equivalents total daily dose) alone or in combination ≥ 6 months and that has been taken at a stable dose for at least 1 month prior to enrolment (v1)
Descrizione

Asthma Treatment Protocols | inhaled steroids | Fluticasone propionate Dry Powder Inhaler

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0004096
UMLS CUI [1,2]
C0040808
UMLS CUI [2]
C2065041
UMLS CUI [3,1]
C0117996
UMLS CUI [3,2]
C1967611
4. additional maintenance asthma controller medications must be given at a stable dose for at least 1 month prior to v1.
Descrizione

Additional medication therapy required Asthma control

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3494715
UMLS CUI [1,2]
C0004096
UMLS CUI [1,3]
C0243148
5. at enrolment (v1) the subject must have a predicted normal value (pnv) for the morning pre-bronchodilator (bd) fev1>50% and more than 1l.
Descrizione

pre bronchodilator FEV1 Morning

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2599602
UMLS CUI [1,2]
C0748133
UMLS CUI [1,3]
C0332170
6. post-bd reversibility in fev1 of ≥12% and ≥200 ml at enrolment (v1).
Descrizione

post bronchodilator Forced Expiratory Volume in 1 Second Reversibility

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2599594
UMLS CUI [1,2]
C3830088
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. history of interstitial lung disease, chronic obstructive pulmonary disease (copd), or other clinically significant lung disease other than asthma.
Descrizione

Lung Diseases, Interstitial | Chronic Obstructive Airway Disease | Other Lung diseases | Asthma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0206062
UMLS CUI [2]
C0024117
UMLS CUI [3,1]
C0205394
UMLS CUI [3,2]
C0024115
UMLS CUI [4]
C0004096
2. history of anaphylaxis following any biologic therapy.
Descrizione

Anaphylaxis Following Biological Response Modifier Therapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0002792
UMLS CUI [1,2]
C0332282
UMLS CUI [1,3]
C0005527
3. hepatitis b, c or hiv
Descrizione

Hepatitis B | Hepatitis C | HIV

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019163
UMLS CUI [2]
C0019196
UMLS CUI [3]
C0019682
4. pregnant or breastfeeding
Descrizione

Pregnancy | Breast Feeding

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
5. history of cancer
Descrizione

Malignant Neoplasms

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006826
6. current tobacco smoking or a history of tobacco smoking for ≥10 pack-years.
Descrizione

Current Smoker | Smoking cigarettes: ____ pack-years history

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3241966
UMLS CUI [2]
C2230126
7. previous receipt of tralokinumab
Descrizione

Received tralokinumab

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514756
UMLS CUI [1,2]
C3658667
Ritorna all'inizio della pagina

Similar models

Eligibility Asthma NCT02449473

1 moduli
  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT02449473
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
1. age 18 to 75 years
boolean
C0001779 (UMLS CUI [1])
Asthma
Item
2. documented physician-diagnosed asthma for at least 12 months prior to enrolment (v1)
boolean
C0004096 (UMLS CUI [1])
Asthma Treatment Protocols | inhaled steroids | Fluticasone propionate Dry Powder Inhaler
Item
3. documented treatment with an asthma controller regimen requiring treatment with ics (minimum dose of ≥ 250 ug fluticasone propionate via dry powder inhaler equivalents total daily dose) alone or in combination ≥ 6 months and that has been taken at a stable dose for at least 1 month prior to enrolment (v1)
boolean
C0004096 (UMLS CUI [1,1])
C0040808 (UMLS CUI [1,2])
C2065041 (UMLS CUI [2])
C0117996 (UMLS CUI [3,1])
C1967611 (UMLS CUI [3,2])
Additional medication therapy required Asthma control
Item
4. additional maintenance asthma controller medications must be given at a stable dose for at least 1 month prior to v1.
boolean
C3494715 (UMLS CUI [1,1])
C0004096 (UMLS CUI [1,2])
C0243148 (UMLS CUI [1,3])
pre bronchodilator FEV1 Morning
Item
5. at enrolment (v1) the subject must have a predicted normal value (pnv) for the morning pre-bronchodilator (bd) fev1>50% and more than 1l.
boolean
C2599602 (UMLS CUI [1,1])
C0748133 (UMLS CUI [1,2])
C0332170 (UMLS CUI [1,3])
post bronchodilator Forced Expiratory Volume in 1 Second Reversibility
Item
6. post-bd reversibility in fev1 of ≥12% and ≥200 ml at enrolment (v1).
boolean
C2599594 (UMLS CUI [1,1])
C3830088 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Lung Diseases, Interstitial | Chronic Obstructive Airway Disease | Other Lung diseases | Asthma
Item
1. history of interstitial lung disease, chronic obstructive pulmonary disease (copd), or other clinically significant lung disease other than asthma.
boolean
C0206062 (UMLS CUI [1])
C0024117 (UMLS CUI [2])
C0205394 (UMLS CUI [3,1])
C0024115 (UMLS CUI [3,2])
C0004096 (UMLS CUI [4])
Anaphylaxis Following Biological Response Modifier Therapy
Item
2. history of anaphylaxis following any biologic therapy.
boolean
C0002792 (UMLS CUI [1,1])
C0332282 (UMLS CUI [1,2])
C0005527 (UMLS CUI [1,3])
Hepatitis B | Hepatitis C | HIV
Item
3. hepatitis b, c or hiv
boolean
C0019163 (UMLS CUI [1])
C0019196 (UMLS CUI [2])
C0019682 (UMLS CUI [3])
Pregnancy | Breast Feeding
Item
4. pregnant or breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Malignant Neoplasms
Item
5. history of cancer
boolean
C0006826 (UMLS CUI [1])
Current Smoker | Smoking cigarettes: ____ pack-years history
Item
6. current tobacco smoking or a history of tobacco smoking for ≥10 pack-years.
boolean
C3241966 (UMLS CUI [1])
C2230126 (UMLS CUI [2])
Received tralokinumab
Item
7. previous receipt of tralokinumab
boolean
C1514756 (UMLS CUI [1,1])
C3658667 (UMLS CUI [1,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial